A Study of ASN007 in Patients With Advanced Solid Tumors

Study Overview

The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.

Study Description

A Phase 1, Open-Label, Dose-Finding Study of ASN007 in Patients with Advanced Solid Tumors

  • ClinicalTrials.gov Identifier: NCT03415126
  • Protocol Number: 18-228
  • Principal Investigator: Glen Weiss
  • Principal Investigator: Central PIO

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000